LHRHa

DRUG5 trials

Sponsors

Cougar Biotechnology, Inc., Imperial College London, M.D. Anderson Cancer Center, University of Sydney, Janssen Pharmaceutica N.V., Belgium

Conditions

Prostate CancerProstatic Neoplasms

Phase 2

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

CompletedNCT01088529

Cougar Biotechnology, Inc.Prostate Cancer

Start: 2009-12-31End: 2013-03-31Updated: 2014-05-15

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

CompletedNCT01946165

M.D. Anderson Cancer CenterProstate Cancer

Start: 2013-10-31End: 2017-07-28Updated: 2019-12-06

Phase 3

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

Active, not recruitingNCT02446444

University of SydneyProstatic Neoplasms

Start: 2014-03-01End: 2026-06-01Updated: 2026-05-06

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Active, not recruitingNCT04557059

Janssen Pharmaceutica N.V., BelgiumProstatic Neoplasms

Start: 2020-11-12End: 2031-09-15Updated: 2026-08-28

Unknown Phase

Mild Cognitive Impairment in Men Following Androgen Deprivation

WithdrawnNCT01691976

Imperial College LondonProstate Cancer

Start: 2012-10-31End: 2013-12-31Updated: 2020-11-20

Related Papers

Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).

Journal of Clinical Oncology2024-01-292 citations

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk of biochemical recurrence (BCR) after radical prostatectomy (RP) in the ongoing phase 3 PRIMORDIUM study.

Journal of Clinical Oncology2024-01-291 citations

Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Cancer

JAMA Network Open2023-10-062 citations

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).

Journal of Clinical Oncology2018-02-209 citations

Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303).

Journal of Clinical Oncology2017-05-201 citations

Neoadjuvant enzalutamide (ENZA) and abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus AA+ LHRHa in localized high-risk prostate cancer (LHRPC).

Journal of Clinical Oncology2016-05-2013 citations

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).

Journal of Clinical Oncology2016-05-201 citations

Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa.

Journal of Clinical Oncology2015-05-207 citations

Effects of preoperative abiraterone acetate (AA) plus enzalutamide (E) and leuprolide acetate (LHRHa) versus AA and LHRHa in localized high-risk prostate cancer (LHRPC).

Journal of Clinical Oncology2015-05-201 citations